Rottapharm Biotech presents recent results on CR10049, the first OA-targeted kinase inhibitor for the treatment of the inflammatory osteoarthritis (OA) phenotype, at the OARSI World Congress on OA
Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that new exciting preclinical data supporting the advancement of CR10049 (a targeted kinase inhibitor for the inflammatory OA phenotype) have been presented at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, held April 24 – 27, 2025 in Incheon, South Korea